Charles River Labs (CRL) PT Lowered to $265 at Evercore ISI
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Charles River Laboratories (CRL) Tops Q1 EPS by 21c; offers guidance
May 9, 2024 7:05 AM EDTCharles River Laboratories (NYSE: CRL) reported Q1 EPS of $2.27, $0.21 better than the analyst estimate of $2.06. Revenue for the quarter came in at $1.01 billion versus the consensus estimate of $992.31 million.
GUIDANCE:
Charles River Laboratories sees FY2024 EPS of $10.90-$11.40, versus the... More
